Location & Type arrow_drop_up Concepts arrow_drop_down Orgs arrow_drop_down
Filter by Concept
#1
Jonathan Friedberg
Jonathan Friedberg
The coonsoldated Department of Psychatry, the Neuroscience Program, Harvard Medical School, Boston, Mass, Consolidated Department of Psychiatry, the Neuro‐science ...
Known for star star star star star
Indolent Lymphoma | Phase Iii | Free Survival | Evaluate Vitamin
#2
Jorge Enrique E Romaguera
Jorge Enrique E Romaguera
Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
Known for star star star star star_border
Mantle Lymphoma | Response Rate | Advisory Committees | Entitys Board

#3
Julie Marie Vose
Julie Marie Vose
From the Section of Oncology-Hematology, Department of Internal Medicine, University of Nebraska Medical Center the Department of Internal Medicine, Omaha Veterans Affairs ...
Known for star star star star star_border
Advisory Committees | Entitys Board | Follicular Lymphoma | Speakers Bureau
#4
Jason Robert Westin
Jason Robert Westin
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Unit 429, 1515 Holcombe Blvd, 77030, Houston, TX, USA
Known for star star star star star_border
Advisory Committees | Entitys Board | B-Cell Lymphoma | Speakers Bureau
#5
Corrado Tarella
Corrado Tarella
Haematology and Cell Therapy Unit, Azienda Ospedaliera Ordine Mauriziano, Torino, Italy Molecular Biotechnology Center, University Department of Biotechnology and Life ...
Known for star star star star star_border
Follicular Lymphoma | Advisory Committees | Bone Marrow | Speakers Bureau
#6
Eva K. Kimby
Eva K. Kimby
Department of Medicine, Section of Hematology, Danderyd Hospital, Danderyd, and the Department of Clinical Immunology, Huddinge Hospital, Huddinge, Sweden
Known for star star star star star_border
Follicular Lymphoma | Chronic Lymphocytic Leukemia | Advisory Committees | Rituximab Maintenance
#7
Krimo Bouabdallah
Krimo Bouabdallah
CHU Bordeaux, Service d’Hématologie et Thérapie Cellulaire, Bordeaux, France
Known for star star star star star_border
Advisory Committees | Entitys Board | Speakers Bureau | Intensive Chemotherapy
#8
Harald JR. Holte
Harald JR. Holte
From the Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.J.S.); the Hematopoietic Cellular Therapy Program, University of Chicago ...
Known for star star star star star_border
Advisory Committees | Entitys Board | Follicular Lymphoma | High-Dose Therapy
#9
Anca A. Prica
Anca A. Prica
From the Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital & Women's College Hospital, University of Toronto, 610 University Ave, Suite ...
Known for star star star star star_border
Hematologic Malignancies | Advisory Committees | Drug Wastage | Entitys Board
#10
David C. Hodgson
David C. Hodgson
Division of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada, ; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada, ;
Known for star star star star star_border
Hodgkin Lymphoma | Radiation Therapy | Breast Cancer | Late Effects
#11
Silvia Mappa
Silvia Mappa
Unit of Lymphoid Malignancies, Department of Onco-Hematology, San Raffaele Scientific Institute, Milan, Italy,
Known for star star star star star_border
Chronic Liver | Bay 80-6946 | Burkitt Lymphoma | Phase 2
#12
Martin Mohren
Martin Mohren
From University Hospital Magdeburg, Division of Cardiology (A.G., M.A., A.A., H.U.K.), Institute of Experimental Internal Medicine (U.L., C.R), Division of Hematology/Oncology ...
Known for star star star star star_border
Acute Leukaemia | Capillary Blood Count | Corticosteroid Injection | Willebrand Factor
#13
Ana Kostic
Ana Kostic
Juno Therapeutics, Inc., a Celgene Company, Seattle, WA
Known for star star star star star_border
Equity Ownership | Speakers Bureau | Lisocabtagene Maraleucel | Transcend Nhl
#14
Roswitha Forstpointner
Roswitha Forstpointner
Department of Internal Medicine III, Ludwig-Maximilians-University Hospital Munich, Munich, Germany
Known for star star star star star_border
Follicular Lymphoma | Rituximab Maintenance | Response Duration | Stem Cells
#15
E. Ellen Shrader
E. Ellen Shrader
Authors' Affiliations: Massey Cancer Center; Departments of Internal Medicine, Biostatistics, Microbiology and Immunology, and Biochemistry and Molecular Biology, and The ...
Known for star star star star star_border
Indolent B-Cell Lymphoma | Advanced Solid Tumors | Acute Leukemia | Myelodysplastic Syndrome
#16
Adam M. Ackerman
Adam M. Ackerman
MGH Cancer Center, Massachusetts General Hospital, Boston, MA USA
Known for star star star star star_border
Pathologic Features | Burkitt Lymphoma | Medullary Plasmacytomas | Bcl2 Rearrangement
#17
Chengqing Wu
Chengqing Wu
Statistics, Celgene International, Boudry, Switzerland
Known for star star star star star_border
Advisory Committees | Entitys Board | ≥ 70 | Phase Iii

 

Recently Asked Questions

View all FAQs

Microvascular Angina The microvascular angina is a kind of angina caused by a reduced blood flow to the small arteries of the heart. Usually the arteries expand to an increased...

 

Anorexia Nervosa Anorexia nervosa is an eating disorder that is characterized by an intense fear of gaining weight, leading to severe restrictions in food intake and...

 

Siderblastic Anemia Siderblastic anemia is a type of anemia characterized by the presence of ringed sideroblasts in bone marrow. Sideroblasts are progenitor cells that have...

 

Ependymoma Ependymoma is a type of brain tumor that arises from the ependymal cells lining the ventricles or central canal of the spinal cord. These cells are...

 

Hypnic Headache A hypnic headache is a type of headache that occurs when you are falling asleep. The pain is usually dull and throbbing and is felt on both sides of the...

 

Two-Year Follow-Up Of Transcend Nhl 001, A Multicenter Phase 1 Study Of...

[ PUBLICATION ] Abstract Background : LBCLs are prevalent and aggressive subtypes of NHL, with limited treatment options and historically poor outcomes in the third- or later-line setting. Liso-cel is an ...
Known for star star star star star
Consultancy Honoraria | Speakers Bureau | Transcend Nhl | Advisory Committees

Cd5-Positive Marginal Zone Lymphoma: Clinical Characteristics Of The Mskcc...

[ PUBLICATION ] ... Zone Lymphoma (MZL) includes three subtypes of indolent lymphoma: splenic MZL, extranodal MZL of mucosa-associated lymphoid tissue (MALT) and nodal MZL. The diagnosis of MZL is often made ...
Known for star star star star star
Funding Consultancy | Marginal Zone | Cd5- Mzl | Seattle Genetics

Long-Term Efficacy And Safety From The Copanlisib Chronos-1 Study In Patients...

[ PUBLICATION ] Abstract Introduction: We have previously reported that treatment of patients with relapsed or refractory indolent B-cell lymphoma with the pan-class I phosphatidylinositol 3-kinase ...
Known for star star star star star
Advisory Committees | Entitys Board | Speakers Bureau | Consultancy Honoraria

Outcomes For Patients With Pre-Existing Diabetes Or Hypertension Treated With...

[ PUBLICATION ] Abstract Introduction: We previously reported that treatment of patients with relapsed or refractory indolent B-cell lymphoma with the pan-class I phosphatidylinositol 3-kinase (PI3K) ...
Known for star star star star star_half
Advisory Committees | Entitys Board | Speakers Bureau | Membership Entity

Impact Of Induction Regimen And Consolidative Stem Cell Transplantation In...

[ PUBLICATION ] Abstract Background DHL are high-grade B-cell lymphomas (BCL) characterized by dual gene rearrangements (RA) of MYC and either BCL2 or BCL6. Outcomes are ...
Known for star star star star star_half
Induction Regimen | Primary Refractory | Consolidative Sct | Hit Lymphoma

Preliminary Results Of A Phase Ii Study Of Single Agent Bay 80-6946, A Novel Pi3k...

[ PUBLICATION ] ... with indolent or aggressive lymphoma subtypes that have progressed after standard thera
Known for star star star star star_half
Aggressive Lymphoma | Bay 80-6946 | Single Agent | Speakers Bureau

Outcomes For Patients With High-Risk Relapsed Or Refractory Indolent B-Cell...

[ PUBLICATION ] Abstract Introduction: Previous studies indicate that follicular lymphoma patients who have progression of disease (POD) within 24 months (ie POD24) of receiving frontline ...
Known for star star star star star_half
Advisory Committees | Entitys Board | Speakers Bureau | Membership Entity

Single-Cell Profiling Reveals Clinically Relevant Evolutionary Trajectories And...

[ PUBLICATION ] ... Follicular lymphoma (FL) is an indolent lymphoma of mature B-cells but may transform to a more aggressive histology, most commonly diffuse large B cell lymphoma. Recurrent mutations ...
Known for star star star star star_half
Follicular Lymphoma | Consultancy Honoraria | Alternate Biologies | Speakers Bureau

Transcend Nhl 001: Immunotherapy With The Cd19-Directed Car T-Cell Product...

[ PUBLICATION ] ... non-Hodgkin lymphoma (Turtle, ASCO 2016), we are conducting a multicenter phase 1 trial of JCAR017 in R/R diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) ...
Known for star star star star star_border
Response Rates | Juno Therapeutics | Product Jcar017 | Directed Car

A Phase 1b Study Of Cc-122 In Combination With Obinutuzumab (Ga101) In Relapsed...

[ PUBLICATION ] Abstract Background: CC-122, a pleiotropic pathway modifier, modulates the cullin 4 ring E3 ligase complex, which results in recruitment and degradation of Aiolos and Ikaros. This ...
Known for star star star star star_border
Advisory Committees | Entitys Board | Speakers Bureau | Membership Entity